Declined by a machine? The end of the unexplainable no

Your client is 44 years old, runs half marathons and hasn’t seen the inside of a hospital since her second child was born. She applies for a $750,000 term policy through one of those no-exam accelerated programs, the kind that promises an answer in days instead of weeks. The answer arrives fast, all right: Table 2. No explanation.

Nobody drew blood. Nobody checked her blood pressure. So what happened?

An algorithm happened. If you sell life insurance in 2026, you need to know what that algorithm read, what the new rules say it can and cannot do, and what you can do for your client when it gets something wrong.

What the machine reads

Accelerated underwriting decides whether to approve, refer or decline without labs by pulling third-party data the moment your client signs the authorization. Three sources do most of the heavy lifting.

Prescription histories come first. Data vendors compile years of pharmacy fill records, and the model reads them the way an old-school underwriter once read lab slips. A statin says one thing. A statin plus two blood pressure medications plus something for sleep apnea says another. What the records don’t include is why a drug was prescribed, and that’s where trouble starts. An antidepressant used off-label for migraines can read as a mood disorder. A one-time painkiller script after knee surgery can look like something it isn’t.

Then there’s MIB, the industry’s shared record of prior application activity. If your client applied elsewhere three years ago and disclosed a condition, that coding follows them to your case.

Third, many programs pull credit-based insurance scores, motor vehicle records and other public data. The theory is that financial stability and safe driving correlate with mortality. The argument regulators keep having is about what else that data correlates with.

The model weighs everything and does one of three things: approves at a rate class, refers the file to a human underwriter, or declines or reprices. The referrals are invisible to your client. The declines and the surprise table ratings are not.

The rulebook caught up

For years, the technology ran ahead of regulation. That era is closing. Three developments now shape what carriers can do with these models, and each development hands advisors something useful.

Start with the National Association of Insurance Commissioners. Its model bulletin on insurers’ use of artificial intelligence systems, adopted in December 2023, reminds carriers that existing law on unfair trade practices and unfair discrimination applies fully to algorithmic decisions, and it expects a written governance program covering testing, bias checks and oversight of the vendors supplying the data. More than half the states have adopted the bulletin or something close to it. In January 2026, the NAIC began piloting an AI examination tool that state regulators will use in market conduct exams. In plain terms, carriers now must be able to document and defend what their models do, because examiners have started asking.

Colorado went further. Under Senate Bill 21-169, insurers there cannot use external consumer data, or algorithms and predictive models built on it, in ways that unfairly discriminate based on race, color, national or ethnic origin, religion, sex, sexual orientation, disability, gender identity or gender expression. The Division of Insurance’s governance regulation has bound life insurers since late 2023 and requires an annual compliance attestation. In October 2025, the state extended the same framework to auto insurers and health plans. A companion rule that would force statistical testing of underwriting outcomes by race and ethnicity is still in draft form, but nobody in the industry doubts where Colorado is headed.

New York State got specific about disclosure, which is where advisors gain the most leverage. The Department of Financial Services’ Insurance Circular Letter No. 7, issued in July 2024, tells every insurer licensed in the state that when an adverse underwriting or pricing decision comes out of an AI system or external data, the reasons given to the applicant should include all the information the decision rested on, down to the specific source. A carrier cannot point to the proprietary nature of a vendor’s model to dodge that. Applicants are also owed a way to review the underlying data for accuracy, and they can request the specific data that produced the decision.

When the algorithm says no

When you combine those rules, you create a functional playbook.

It starts before the application. Ask about every prescription from the past five to seven years, including drugs filled once and abandoned, drugs prescribed off-label and drugs tied to a condition that resolved long ago. The database will surface all of it anyway, so the application should explain it first. A short cover letter from you to the underwriter, supplying the context a pharmacy record can’t, remains one of the most valuable pieces of paper in this business.

When a case comes back flagged, repriced or declined, put a question to the carrier in writing: what were the specific reasons, and what were the specific data sources? In New York, that answer is expected of them. Everywhere else, most carriers can produce it, and the federal Fair Credit Reporting Act independently gives your client rights when a third-party consumer report drove the adverse action, including a free copy of the report and a process for disputing errors.

Then check the data itself. Have the client request their MIB file, which is free, along with their prescription history report from the carrier’s data vendor. Miscoded drugs, stale records and other people’s information blended into a file all happen more often than anyone likes to admit. A successful dispute followed by a request for reconsideration can reverse a decline without ever changing carriers.

If the data is accurate but the model’s conclusion feels harsh, change the process instead. Most carriers can shift an accelerated case into full traditional underwriting, where labs, an exam and an attending physician statement give a human underwriter a fuller picture than a pharmacy printout. And because every carrier’s model weighs the same data differently, shopping the case around is not desperation. It’s the job.

The part of underwriting that stays human

None of this slows the technology down, and it isn’t meant to. Instant-decision underwriting is genuinely good for most clients most of the time. What the new rules end is the era of the unexplainable no. Carriers now must know why their models decide what they decide, and increasingly they have to say so.

Someone still must ask, though. Regulations create rights; they don’t exercise them. That part is yours. The advisors who understand what the machine read, and what the law now requires a carrier to reveal, will place cases this year that would have died quietly five years ago.

© Entire contents copyright 2026 by InsuranceNewsNet.com Inc. All rights reserved. No part of this article may be reprinted without the expressed written consent from InsuranceNewsNet.com.

The post Declined by a machine? The end of the unexplainable no appeared first on Insurance News | InsuranceNewsNet.